Oncology Central

High incidence of febrile neutropenia seen following adjuvant chemotherapy with docetaxel plus cyclophosphamide for early breast cancer


Lakhanpal et al. conducted a multicenter retrospective audit in seven Australian centers to determine the incidence of febrile neutropenia (FN) and neutropenia associated with the use of docetaxel plus cyclophosphamide (TC) in women with early breast cancer who did not receive primary prophylaxis with G-CSF or antibiotics [1]. Of the 300 evaluable female patients 73 (24.3%) developed FN with the incidence higher after cycle 1 of TC.

To view restricted content, please:

Leave A Comment